LY255283 is a competitive leukotriene B4 receptor antagonist, with an IC50 of about 100 nM. It is somewhat selective for the BLT2 receptor, since IC50 values at the BLT1 receptor are >10 μM. LY255283 reduces airway obstruction in animal models of asthma.
| Molecular Weight | 360.45 |
| Formula | C19H28N4O3 |
| CAS Number | 117690-79-6 |
| Solubility (25°C) | DMSO: ≥20 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[4] S A Silbaugh, et al. Pulmonary actions of LY255283, a leukotriene B4 receptor antagonist
| Related Leukotriene Receptor Products |
|---|
| Piriprost potassium
Piriprost (U-60,257B) potassium is an inhibitor of leukotriene synthesis. |
| LTB4 antagonist 3
LTB4 antagonist 3 is a leukotriene B4 (LTB4) antagonist with an IC50 value of 477 nM. |
| LTB4 antagonist 1
LTB4 antagonist 1, a carboxamide-acid compound, is a potent Leukotriene B4 (LTB4) antagonist with an IC50 of 288 nM. |
| LTB4 antagonist 2
LTB4 antagonist 2, a carboxamide-acid compound, is an antagonist of leukotriene B4 (LTB4) with potentially anti-inflammatory activity. |
| Tipelukast
Tipelukast is an orally bioavailable leukotriene receptor antagonist with anti-inflammatory activity for studies related to asthma and non-alcoholic steatohepatitis (NASH). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
